Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.82 |
| ▸ | GSK3B | P49841 | 13/20 | 0.82 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.60 |
| ▸ | CDK1 | P06493 | 3/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14427488 | 0.91 | CDK2 (1.00) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427362 | 0.91 | CDK2 (1.00) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427538 | 0.85 | CDK2 (1.00) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427485 | 0.82 | CDK2 (1.00) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427515 | 0.82 | CDK2 (0.82) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427476 | 0.81 | CDK2 (0.93) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427495 | 0.80 | CDK2 (1.00) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL5451201 | 0.80 | CDK2 (0.75) | CDK2GSK3BMAPKAPK2CDK1CHEK1 | |
| SCHEMBL14427430 | 0.80 | GSK3B (0.52) | CDK2GSK3BCDK1CCNE1 | |
| SCHEMBL14427513 | 0.79 | CDK2 (1.00) | CDK2GSK3BMAPKAPK2CDK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179161-A1 | Pyrazolopyrimidine compounds and their use in medicine | VERNALIS (CAMBRIDGE) LIMITED. (GB) | 2007-08-02 | — | — | US | disclosed |
| US-20070179161-A1 | Pyrazolopyrimidine compounds and their use in medicine | VERNALIS (CAMBRIDGE) LIMITED. (GB) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179161-A1 | Pyrazolopyrimidine compounds and their use in medicine | ROS1, ALK, NOX1 | CDK2 228/4885GSK3B 409/4885MAPKAPK2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.